Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23 | Zendy

SherriAnn M. BurnettBowie | Zendy; Benjamin Z. Leder | Zendy; Maria Paula Henao | Zendy; Chantel M. Baldwin | Zendy; Ivor S. Douglas | Zendy; Joel S. Finkelstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Author(s) -

SherriAnn M. BurnettBowie,

Benjamin Z. Leder,

Maria Paula Henao,

Chantel M. Baldwin,

Ivor S. Douglas,

Joel S. Finkelstein

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.10030911

Subject(s) - ergocalciferol , medicine , endocrinology , vitamin d and neurology , fibroblast growth factor 23 , parathyroid hormone , placebo , excretion , cholecalciferol , calcium , pathology , alternative medicine

Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research